Results 161 to 170 of about 293,293 (239)

OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With Therapeutic Response to Tumor Necrosis Factor Inhibitor

open access: yesArthritis &Rheumatology, EarlyView.
Objective To verify the pathogenesis of the opioid growth factor receptor like‐1 (OGFRL1) loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism.
Wen Xiong   +9 more
wiley   +1 more source

Multimodal Integration of Protein Interactomes With Genomic and Molecular Data Discovers Distinct Rheumatoid Arthritis Endotypes

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease characterized by clinical and molecular heterogeneity, notably in the presence of anti–cyclic citrullinated peptide (CCP) antibodies. Patients with CCP+ RA exhibit more severe disease progression and distinct treatment responses compared to patients with CCP− RA.
Javad Rahimikollu   +10 more
wiley   +1 more source

Genetic diversity and population structure of pearl millet in the Senegalese germplasm. [PDF]

open access: yesPLoS One
Ba A   +9 more
europepmc   +1 more source

Inosine triphosphate pyrophosphatase activity as a potential predictor of methotrexate remission in juvenile idiopathic arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Methotrexate (MTX) is the first‐line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients don't respond. Low inosine‐triphosphate‐pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated ITPA role and the underlying mechanisms in vitro.
Sofia Sindici Forgiarini   +19 more
wiley   +1 more source

SNP [PDF]

open access: yes, 2019
openaire   +1 more source

Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To examine coverage of self‐administered disease‐modifying anti‐rheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022‐2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T‐cell co‐stimulatory modulator, Interleukin‐6 ...
Youngmin Kwon   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy